|
| Cancer types | Cell lines used | Biomarker identified | Clinical relevance | Quantitative techniques used | Reference |
|
| Breast cancer | 21T series of Breast cancer cell lines
HMT-3522-S1, MFM223, HCC202 and HCC2218, HCC1599, HCC1143, HCC1937, MCF7, MCF10A, MDA-MB-453 | TIMM 17A
IDH2, CRABP2, SEC14L2 | Disease prognosis
Disease progression and monitoring | SILAC and LC-MS/MS
SILAC and MALDI-MS/MS | [5]
[44] |
|
| Prostate cancer | PC3, LnCAP, 22Rv1 | Follistatin, chemokine (C-X-C motif) ligand 16, Pentraxin 3, and spondin 2 | Disease progression and monitoring | Two-dimensional chromatography and tandem mass spectrometry
2D-DIGE, MALDI-MS/MS | [76]
[92] |
|
| Lung cancer | 1198 and 1170-I, BEAS-2B and 1799
CL1-0 and CL1-5 | PGP9.5, TCTP, TIMP-2, and TPI
KPNA2 | Disease monitoring
Disease detection and progression monitoring | 2DE and MS
SILAC, LC-MS/MS | [81]
[46] |
|
Gastric cancer
| AGS and MKN7
| GRN
| Disease detection and monitoring | 2D-LC-MS/MS and iTRAQ | [93] |
|
| Pancreatic cancer | PANC1, BxPc3, MIA-PaCa2, SU.86.86 | Anterior gradient homolog 2, syncollin, olfactomedin-4, polymeric immunoglobulin
receptor, and collagen alpha-1(VI) chain | Early disease detection and monitoring | LC-MS/MS, ELISA | [94] |
|
| Colorectal cancer | Tumor samples were cultured in vitro | EFEMP2 | Detection and monitoring | 1D-LC-MS/MS | [95] |
|
| Head and Neck cancer | SCC4, HSC2, SCC38, and AMOSIII | alpha-enolase, peptidyl prolyl isomerase A/cyclophilin A, 14-3-3 z, heterogeneous ribonucleoprotein K, and 14-3-3 s | Disease detection and progression monitoring | LC-MS/MS, western blot | [96] |
|
| Oral cancer | OEC-M1 and SCC4
OEC-M1 and SCC4 | Mac-2 BP
Guanylate-binding protein 1 (GBP1) | Early detection of disease
Disease detection and progression | MALDI-TOF MS
1D and LC-MS/MS | [97]
[98] |
|
| Renal cell carcinoma | 786-O, Caki-1, A498, ACHN OS-RC-2, HK-2, HUVEC | FoxM1 | Detection and potential drug target | IHC, western blot, ELISA | [99] |
|
